These ApoEVs were modified to express a high-mannose structure to target DC-SIGN on the monocyte-derived DCs to enhance vesicle internalization, thus further initiating and activating tumor-specific CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.